Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | NEK2 | P51955 | 1/20 | 0.48 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | EDNRA | P25101 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11893013 | 0.88 | CHEK1 (0.53) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL22080283 | 0.84 | CYP1A2 (0.46) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL13486826 | 0.83 | CHEK1 (0.48) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL3238496 | 0.82 | GABRA1 (0.57) | CYP1A2CYP2C19HTTGABRA1GABRB2 | |
| SCHEMBL8720110 | 0.82 | CHEK1 (0.65) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL27019222 | 0.82 | GABRA1 (0.40) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL12703140 | 0.82 | CHEK1 (0.47) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL14196713 | 0.80 | CYP1A2 (0.46) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL31644190 | 0.80 | TDP1 (0.56) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL13561468 | 0.79 | CHEK1 (0.44) | CYP1A2CYP2C19HTTHIF1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| US-20230312498-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2023-10-05 | — | — | US | disclosed |
| US-11718595-B2 | Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230140941-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-05-11 | — | — | US | disclosed |
| WO-2023063884-A2 | GENERATION OF CHIRAL SULFINATE ESTERS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2023-04-20 | — | — | WO | disclosed |
| US-20220411390-A1 | MODULATION OF BACTERIAL QUORUM SENSING WITH SYNTHETIC LIGANDS | WISCONSIN ALUMNI RES FOUND (US) | 2022-12-29 | — | — | US | disclosed |
| US-20210317097-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2021-10-14 | — | — | US | disclosed |
| WO-2021183970-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-09-16 | — | — | WO | disclosed |
| US-10894777-B2 | TG2 inhibitor piperazine compounds and uses thereof | UNIVERSITY OF OTTAWA (CA) | 2021-01-19 | — | — | US | disclosed |
| WO-2017179018-A1 | TG2 INHIBITOR COMPOUNDS AND USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2017-10-19 | — | — | WO | disclosed |
| WO-2016131098-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-08-25 | — | — | WO | disclosed |
| US-20120028915-A1 | 6\"-AMINO-6\"-DEOXYGALACTOSYLCERAMIDES | THE SCRIPPS RESEACH INSTITUTE (US) | 2012-02-02 | — | — | US | disclosed |
| US-7989423-B2 | 6″-amino-6″-deoxygalactosylceramides | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100137231-A1 | 6\"-AMINO-6\"-DEOXYGALACTOSYLCERAMIDES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-06-03 | — | — | US | disclosed |
| US-7288571-B2 | Thyroid receptor ligands and method II | KARO BIO AB (SE) | 2007-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140941-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | CYP1A2 3599/4885CYP2C19 4404/4885HTT 4360/4885 |
| US-11845715-B2 | — | NLRP3, PYCARD, NOD1 | CYP1A2 4028/4885CYP2C19 4158/4885HTT 543/4885 |
| US-20100137231-A1 | 6\"-AMINO-6\"-DEOXYGALACTOSYLCERAMIDES | FUT6, GALNT6, ST6GAL1 | CYP1A2 3652/4885CYP2C19 4091/4885HTT 3055/4885 |
| US-20220411390-A1 | MODULATION OF BACTERIAL QUORUM SENSING WITH SYNTHETIC LIGANDS | AHCYL1, EBPL, AIP | CYP1A2 3568/4885CYP2C19 4566/4885HTT 2151/4885 |
| US-20210317097-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | CYP1A2 3491/4885CYP2C19 4287/4885HTT 4230/4885 |
| US-20120028915-A1 | 6\"-AMINO-6\"-DEOXYGALACTOSYLCERAMIDES | FUT6, GALNT6, ST6GAL1 | CYP1A2 3652/4885CYP2C19 4091/4885HTT 3055/4885 |
| US-20230312498-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | CYP1A2 3491/4885CYP2C19 4287/4885HTT 4230/4885 |
| US-11718595-B2 | Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors | MAPK1, MAPK8, MAPK4 | CYP1A2 3491/4885CYP2C19 4287/4885HTT 4230/4885 |
| US-10894777-B2 | TG2 inhibitor piperazine compounds and uses thereof | TGM2, TGM1, TGM3 | CYP1A2 1886/4885CYP2C19 1550/4885HTT 1616/4885 |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | CYP1A2 1772/4885CYP2C19 1899/4885HTT 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.